Display options
Share it on

Kidney Res Clin Pract. 2015 Jun;34(2):69-75. doi: 10.1016/j.krcp.2015.03.003. Epub 2015 Apr 09.

Nonimmunologic targets of immunosuppressive agents in podocytes.

Kidney research and clinical practice

Tae-Hyun Yoo, Alessia Fornoni

Affiliations

  1. Department of Internal Medicine, College of Medicine, Yonsei University, Seoul, Korea ; Division of Nephrology and Hypertension, Department of Medicine, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA ; Peggy and Harold Katz Family Drug Discovery Center, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA.
  2. Division of Nephrology and Hypertension, Department of Medicine, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA ; Peggy and Harold Katz Family Drug Discovery Center, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA.

PMID: 26484025 PMCID: PMC4570600 DOI: 10.1016/j.krcp.2015.03.003

Abstract

Proteinuria is a characteristic finding in glomerular diseases and is closely associated with renal outcomes. In addition, therapeutic interventions that reduce proteinuria improve renal prognosis. Accumulating evidence has demonstrated that podocytes act as key modulators of glomerular injury and proteinuria. The podocyte, or glomerular visceral epithelial cell, is a highly specialized and differentiated cell that forms interdigitated foot processes with neighboring podocytes, which are bridged together by an extracellular structure known as the "slit diaphragm" (SD). The SD acts as a size- and charge-selective barrier to plasma protein. Derangement of SD structure or loss of SD-associated protein results in podocyte injury and proteinuria. During the past decades, several immune-modulating agents have been used for the treatment of glomerular diseases and for the reduction of proteinuria. Interestingly, recent studies have demonstrated that immunosuppressive agents can have a direct effect on the SD-associated proteins and stabilize actin cytoskeleton in podocyte and have therefore introduced the concept of nonimmunologic mechanism of renoprotection by immunomodulators. This review focuses on the evidence that immuno-modulating agents directly target podocytes.

Keywords: Immunomodulation; Nephrotic syndrome; Podocyte; Proteinuria

References

  1. Kidney Int. 1999 May;55(5):1885-90 - PubMed
  2. Nephrol Dial Transplant. 1999;14 Suppl 3:74-8 - PubMed
  3. Kidney Int. 2000 Feb;57(2):510-7 - PubMed
  4. Immunology. 2000 Jun;100(2):217-24 - PubMed
  5. Curr Opin Nephrol Hypertens. 2001 Jul;10(4):543-9 - PubMed
  6. Science. 2001 Nov 30;294(5548):1875-8 - PubMed
  7. Physiol Rev. 2003 Jan;83(1):253-307 - PubMed
  8. J Am Soc Nephrol. 2003 Mar;14(3):690-8 - PubMed
  9. Nephrol Dial Transplant. 2003 Aug;18 Suppl 6:vi79-86 - PubMed
  10. Clin Sci (Lond). 1992 Jun;82(6):641-50 - PubMed
  11. J Clin Invest. 2004 May;113(10):1390-7 - PubMed
  12. Clin Sci (Lond). 2004 Aug;107(2):125-36 - PubMed
  13. Genes Dev. 2004 Aug 15;18(16):1926-45 - PubMed
  14. Pediatr Nephrol. 1992 Mar;6(2):140-4 - PubMed
  15. J Clin Invest. 2005 May;115(5):1188-98 - PubMed
  16. Science. 2005 Jun 17;308(5729):1801-4 - PubMed
  17. Nat Genet. 2005 Jul;37(7):739-44 - PubMed
  18. J Am Soc Nephrol. 2005 Sep;16(9):2615-25 - PubMed
  19. Pediatr Nephrol. 2005 Nov;20(11):1660-3 - PubMed
  20. Blood. 2006 Feb 1;107(3):1070-7 - PubMed
  21. Kidney Int. 2005 Dec;68(6):2473-83 - PubMed
  22. Parasitology. 2006 Mar;132(Pt 3):301-13 - PubMed
  23. Am J Physiol Renal Physiol. 2006 Jun;290(6):F1516-24 - PubMed
  24. Nat Rev Drug Discov. 2006 Mar;5(3):185-6 - PubMed
  25. N Engl J Med. 2006 May 4;354(18):1961-3 - PubMed
  26. Kidney Int. 2006 Jun;69(12):2251-60 - PubMed
  27. Kidney Int. 2006 Sep;70(6):1038-45 - PubMed
  28. Nat Clin Pract Nephrol. 2006 Apr;2(4):221-30 - PubMed
  29. N Engl J Med. 2006 Sep 14;355(11):1124-40 - PubMed
  30. J Am Soc Nephrol. 2007 Jan;18(1):29-36 - PubMed
  31. Kidney Int. 2007 Dec;72(12):1429-47 - PubMed
  32. Biochim Biophys Acta. 2008 Sep;1781(9):503-7 - PubMed
  33. Nephron Exp Nephrol. 2008;109(1):e8-19 - PubMed
  34. Nat Med. 2008 Sep;14(9):931-8 - PubMed
  35. Clin Lymphoma Myeloma. 2008 Oct;8(5):277-82 - PubMed
  36. Neurology. 2009 Jan 6;72(1):73-9 - PubMed
  37. Pediatr Nephrol. 2009 Oct;24(10):2051-3 - PubMed
  38. Am J Kidney Dis. 2009 Nov;54(5):945-53 - PubMed
  39. Expert Opin Biol Ther. 2010 Mar;10(3):451-8 - PubMed
  40. Clin Pharm. 1991 Feb;10(2):95-109 - PubMed
  41. Pediatr Nephrol. 2010 Jun;25(6):1017-23 - PubMed
  42. Immunol Rev. 2010 Sep;237(1):264-83 - PubMed
  43. Kidney Int. 2011 May;79(10):1090-8 - PubMed
  44. J Clin Invest. 2011 Jun;121(6):2197-209 - PubMed
  45. J Clin Invest. 2011 Jun;121(6):2181-96 - PubMed
  46. J Clin Invest. 2011 Jun;121(6):2142-5 - PubMed
  47. Sci Transl Med. 2011 Jun 1;3(85):85ra46 - PubMed
  48. Am J Pathol. 2011 Oct;179(4):1719-32 - PubMed
  49. Nat Rev Nephrol. 2011 Nov 01;8(1):52-6 - PubMed
  50. Expert Rev Clin Pharmacol. 2010 Jul;3(4):527-37 - PubMed
  51. Transplant Rev (Orlando). 2012 Jan;26(1):27-9 - PubMed
  52. Nat Rev Nephrol. 2011 Dec 06;8(2):122-8 - PubMed
  53. Free Radic Biol Med. 2013 Oct;63:207-21 - PubMed
  54. Clin J Am Soc Nephrol. 2014 Mar;9(3):609-16 - PubMed
  55. Expert Opin Biol Ther. 2013 Nov;13(11):1557-68 - PubMed
  56. N Engl J Med. 2013 Dec 19;369(25):2416-23 - PubMed
  57. Expert Opin Biol Ther. 2014 May;14(5):563-7 - PubMed
  58. Diabetes. 2014 Jun;63(6):2063-72 - PubMed
  59. J Clin Invest. 2014 Jun;124(6):2307-14 - PubMed
  60. J Am Soc Nephrol. 2015 Jan;26(1):133-47 - PubMed
  61. Clin Sci (Lond). 2015 Jun;128(12):883-93 - PubMed
  62. Kidney Res Clin Pract. 2012 Dec;31(4):205-13 - PubMed
  63. Lancet. 1974 Sep 7;2(7880):556-60 - PubMed
  64. Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7839-43 - PubMed
  65. Clin Exp Immunol. 1995 Jun;100(3):475-9 - PubMed
  66. J Am Soc Nephrol. 1996 Feb;7(2):290-8 - PubMed
  67. Am J Kidney Dis. 1997 Nov;30(5):621-31 - PubMed

Publication Types

Grant support